The principles that govern the evolution of tumors exposed to targeted therapy are poorly understood. Here we modeled the selection and propagation of an amplification in the BRAF oncogene (BRAF amp ) in patient-derived tumor xenografts (PDXs) that were treated with a direct inhibitor of the kinase ERK, either alone or in combination with other ERK signaling inhibitors. Single-cell sequencing and multiplex fluorescence in situ hybridization analyses mapped the emergence of extra-chromosomal amplification in parallel evolutionary trajectories that arose in the same tumor shortly after treatment. The evolutionary selection of BRAF amp was determined by the fitness threshold, the barrier that subclonal populations need to overcome to regain fitness in the presence of therapy. This differed for inhibitors of ERK signaling, suggesting that sequential monotherapy is ineffective and selects for a progressively higher BRAF copy number. Concurrent targeting of the RAF, MEK and ERK kinases, however, imposed a sufficiently high fitness threshold to prevent the propagation of subclones with high-level BRAF amp . When administered on an intermittent schedule, this treatment inhibited tumor growth in 11/11 PDXs of lung cancer or melanoma without apparent toxicity in mice. Thus, gene amplification can be acquired and expanded through parallel evolution, enabling tumors to adapt while maintaining their intratumoral heterogeneity. Treatments that impose the highest fitness threshold will likely prevent the evolution of resistance-causing alterations and, thus, merit testing in patients.
a r t i c l e s Mutations in BRAF are found in ~7% of patients with cancer, particularly in those with melanoma or colorectal, thyroid or lung cancer 1, 2 . The most frequent of these mutations, BRAF V600E , drives tumor growth by hyperactivating the extracellular-signal-regulated kinase (ERK) signaling pathway. Inhibition of RAF, alone or together with its downstream kinase MEK, is effective in slowing the progression of BRAF V600 -mutant melanomas and lung cancers [3] [4] [5] [6] [7] [8] . However, as the tumors adapt to therapy, almost all of the patients succumb to the disease. Several mechanisms of resistance to these drugs have been reported, including mutations in the oncogene NRAS and MEK [9] [10] [11] [12] [13] , BRAF V600E splice variants and BRAF amplification. Whether these are truly acquired or selected during therapy remains under investigation. Durable suppression of ERK signaling is required for maximal antitumor effect, and resistance to these drugs is often associated with reactivated ERK 14, 15 . With this in mind, direct inhibitors of ERK being tested clinically to improve the outcomes of patients with BRAF V600 -mutant cancers.
It is commonly thought that the high mutational rate of cancer cells leads to diversification of the population, after which one clone ultimately gains an advantageous mutation and is able to outgrow the other clones (i.e., sweep) and take over the tumor mass [16] [17] [18] . As selective pressures change, this process is repeated, enabling tumors to adapt to their environment.
Single-cell DNA sequencing is an emerging new technique that enables the identification of genomic alterations at the single-cell level [19] [20] [21] , with the potential to yield a better resolution of the tumor's clonal architecture as compared to that by conventional bulk sequencing. Here we generated patient-derived xenograft (PDX) models and used single-cell DNA sequencing to provide insight into the evolution of resistance during treatment with an ERK inhibitor (ERKi) and to identify therapeutic modalities that prevent this process.
RESULTS
Effect of ERKi treatment in PDX models of lung cancer and melanoma PDX models were derived from patients with BRAF V600E -mutant lung cancer or melanoma. Patients with lung cancer had been previously treated with chemotherapy, as this is a standard treatment for the a r t i c l e s management of stage IV disease. Patients with melanoma were chemotherapy naive, as this is not effective for the disease and, thus, is not used as a first-line of treatment in this setting. The BRAF-mutant models were established from six patients whose cancer had progressed after treatment with a RAF inhibitor (RAFi) or MEK inhibitor (MEKi), and from two patients who were treatment naive ( Table 1 and Supplementary Fig. 1a ). For those patients who were previously on targeted therapy, the models were established from biopsy specimens or pleural effusions that were obtained at the time the patient was found to have progressive disease. As noted above, ERK inhibitors are being clinically tested in an effort to improve outcomes of patients whose cancer progressed after RAFi or MEKi therapy. In light of this, we tested the effect of an ATP-competitive inhibitor (SCH984), which inhibits the kinase activity of ERK and prevents its phosphorylation by MEK 22, 23 . Treatment of mice with SCH984 inhibited growth in three of the six PDX models tested (Fig. 1a) , for which the duration of response lasted several weeks. The tumors that grew after ERKi treatment had diminished sensitivity to this drug in subsequent passages ( Supplementary  Fig. 1b) . Thus, ERKi-monotherapy in BRAF V600E -mutant cancer is limited by the emergence of resistance or de novo insensitivity.
Single-cell copy number profiles in a parental and ERKi-resistant PDX pair Understanding the parameters that control the emergence of ERKi resistance (EiR) might enable the identification of more effective therapies. To this end, we performed bulk and single-cell sequencing in a parental and EiR tumor pair that was derived from PDX1D ( Fig. 1b  and Supplementary Fig. 1c ). This model was established from a patient whose cancer progressed during treatment with the RAFi dabrafenib and retained insensitivity to RAFi monotherapy in athymic mice (see below). Somatic variant analysis of these tumors revealed a close similarity to the patient material from which they were derived ( Supplementary Fig. 1d ). Mutant allele frequencies were not significantly affected by ERKi treatment, and we subsequently focused on copy number (CN) alterations as a potential driver of resistance. For single-cell sequencing, genomic DNA from FACS-sorted single nuclei was amplified by whole-genome amplification and subjected to sparse massively parallel sequencing, as previously described 19, 21, 24 . As compared to a human diploid control, nuclei from the PDX distributed in near-diploid and polyploid populations, which corresponded to mouse stromal cells and human tumor cells, respectively ( Fig. 1c and Supplementary Fig. 1e) .
The CN profiles of the human tumors were complex ( Fig. 1d and Supplementary Fig. 1f,g) , with almost all of the sequenced cells showing gains in chromosomes 6p, 7p, 8q, 16q and 20, and losses in chromosomes 1p, 7q and 8p, some of which are known to recur in the genomes of lung adenocarcinoma cells 25 . Heterogeneous alterations were identified in chromosomes 1, 2p, 3q, 11q, 13, 17q, 21 and X. This genetic diversity enabled the discrimination of parental cells from resistant cells in principal component analysis ( Fig. 1e ) and the inference of distinct subpopulations (A-E) through hierarchical clustering ( Fig. 1d ) and t-distributed stochastic neighbor embedding (t-SNE) analysis ( Supplementary Fig. 1h ). Although both parental and resistant tumors had a high Shannon diversity index ( Supplementary  Fig. 1i ), their subclonal distribution differed due to the selective pressure of therapy ( Fig. 1f) . Parental cells were predominantly found in subpopulations A, B and C and were intermixed with a few cells derived from the resistant tumor ( Fig. 1d,f) . In contrast, the majority of resistant cells clustered in subpopulation E, alongside a single parental cell (Par24), which is probably an earlier precursor of this dominant resistant clone.
BRAF amp is selected and expanded through parallel evolution While searching for CN alterations associated with resistance, we found that parental and resistant cells had progressively higher BRAF segment counts as compared to those in stromal cells ( Fig. 1g) . Although nearly 50% of resistant cells had >6 segment counts, none of the parental cells had values that surpassed this threshold. Fluorescence in situ hybridization (FISH) analysis confirmed a high-level BRAF amp in PDX1D-EiR and PDX1E-EiR tumors, as well as the presence of cells with extra BRAF copies in the parental models ( Fig. 1h) . PDX1E was established from a separate site of progressive disease in patient 1 ( Table 1) . This model was also insensitive to RAFi (see below) and its ERKi-resistant derivative was established independent of PDX1D-EiR. In EiR cells the increase in BRAF CN was greater than the increase in the centromere CN (Fig. 1i) , and the BRAF gene was dispersed in extra-chromosomal regions (Fig. 1j) . As expected, this amplification led to increased BRAF V600E protein expression ( Fig. 1k ) in resistant models. BRAF amp was also identified in PDX25, a PDX model of melanoma with de novo ERKi insensitivity ( Fig. 1a and Supplementary Table 1 ).
The clonal architecture in Figure 1f suggests the emergence of a selective sweep by subclone E after ERKi treatment. Unexpectedly, however, we found that resistant cells harboring high-level BRAF amp were also present in other subclones ( Fig. 2a-d) . A closer evaluation of chromosomes with heterogeneous CN profiles revealed three trajectories leading to high-level BRAF amp ; these were defined by losses in chromosome 2p, chromosome 11q or chromosome 13 ( Fig. 2e) . Multiplex FISH analysis with probes targeting genes in these chromosomal regions (Fig. 2f,g and Supplementary Fig. 2a ) confirmed the presence of three distinct BRAF amp species in PDX1D-EiR: (i) BRAF amp with RB1 (chromosome 13) and ALK (chromosome 2p) loss, or with RB1 and ATM (chromosome 11) loss; (ii) BRAF amp with RB1 loss only; or (iii) BRAF amp without these alterations.
Losses in chromosomes 2p and 11q occurred together ( Fig. 2e) , and probing for ALK or ATM were used as orthogonal approaches to identify the various subclones. The same species were observed a r t i c l e s in the independently derived resistant tumor PDX1E-EiR ( Fig. 1a and Supplementary Figs. 1c,d and 2b) . Thus, under the selective pressure of ERKi treatment, BRAF amp is selected and propagated through parallel evolutionary trajectories that maintain intratumoral genetic heterogeneity.
BRAF amp provides a selective growth advantage in the presence of ERKi treatment To determine whether BRAF amp was sufficient to confer a fitness advantage during ERKi treatment, we established cell lines from PDX1D and PDX1D-EiR ( Fig. 3a ; referred to as 1D and 1D-EiR, respectively). Treatment with the inhibitor suppressed signaling and proliferation less potently in 1D-EiR than in 1D cells, as evidenced by the residual phosphorylation of ERK and its substrate RSK, as well as a right shift in proliferation dose-response curves (Fig. 3b,c) . The effect of another ERKi, Vx11e, was attenuated in a similar manner ( Supplementary Fig.  3a,b ). Short interfering RNAs (siRNAs) targeting BRAF in 1D-EiR cells enabled a more potent inhibition of signaling ( Supplementary  Fig. 3c ) and proliferation ( Fig. 3d ) by the drug. Furthermore, inducing the expression of BRAF V600E in melanoma cells (A375) that were engineered to express BRAF V600E under a doxycycline (Dox)-inducible promoter 26 diminished the inhibition of phospho-ERK and phospho-RSK immediately after ERKi treatment or after longer treatment intervals ( Supplementary Fig. 3d-g) . The expression of two ERK-dependent signaling markers 27 , cyclin D1 and Spry2, was restored to near baseline levels after 48 h of ERKi treatment in Dox-induced cells (Fig. 3e) . Because of these direct and adaptive changes, increased BRAF V600E expression attenuated the anti-proliferative effect of ERKi treatment in a dose-dependent and reversible manner ( Fig. 3f) . Inducing the expression of BRAF V600E conferred a growth advantage only during treatment with the ERKi (Supplementary Fig. 3h) , and when PDX1D-EiR tumors were grown in the absence of such a treatment, there was a decrease in the BRAF CN (Supplementary Fig. 3i) .
A fitness threshold model to explain the selection and propagation of BRAF amp during treatment In addition to attenuating direct ERK inhibition, BRAF amp is a frequent cause of resistance in patients with melanoma who were a r t i c l e s treated with inhibitors of RAF and/or MEK [10] [11] [12] [13] . Notably, BRAF CN gains or amplifications were present in a substantial proportion of patients with melanoma even before exposure to targeted therapy (Fig. 4a) . This suggests that selection of BRAF amp during therapy is a widespread phenomenon in these tumors. To define how this evolutionary selection is determined, we compared the fitness effect of BRAF amp in the presence of RAFi, MEKi or ERKi treatment. BRAF V600E expression attenuated the inhibition of signaling ( Fig. 4b and Supplementary Fig. 4a-c) and conferred a fitness advantage, i.e., continued proliferation in the presence of each drug ( Fig. 4c and Supplementary Fig. 4d ). The level of BRAF V600E expression required to confer a similar fitness increment in the presence of RAFi or MEKi treatment, however, was lower than that of ERKi treatment ( Fig. 4c and Supplementary Fig. 4d) . Thus, the magnitude of amplification required for continued pathway activity and proliferation in the presence of the drug, a cut-off that we refer to as fitness threshold, is drug-dependent, and higher levels of BRAF amp are needed to bypass the effect of direct ERK inhibition.
Sequential therapy may select for progressive increases in BRAF copy number The data suggest that sequential exposure to ERK signaling inhibitors is ineffective and that it serves as a selective gradient for the propagation of tumor subpopulations with a progressively higher BRAF CN (Fig. 4d) . Indeed, bulk sequencing of biopsy specimens from patients after treatment with a RAFi and of matched PDXs exposed to an ERKi revealed a progressive increase in BRAF CN (Fig. 4e) . By comparison, a normal BRAF CN was observed in the sample obtained before RAFi treatment but after exposure to chemotherapy (Fig. 4e) .
Thus, although exposure to chemotherapy may create a permissive environment, this alone seems to be insufficient for the expansion of BRAF amp subpopulations.
The data above suggest that sequential treatment with these drugs is suboptimal in achieving a maximal or durable response in patients. To provide some evidence in support of this, we evaluated the responses of several patients who were treated sequentially with ERK signaling inhibitors. Three patients who were previously on a RAFi and MEKi (RAFi-MEKi) combination therapy failed to respond to ERKi treatment, whereas two targeted therapy-naive patients responded to this agent ( Fig. 4f and Supplementary Table 2 ). Addition of a MEKi after cancer progression on RAFi therapy was also ineffective in four patients with lung cancer ( Fig. 4g and  Supplementary Table 2) , a finding that is in agreement with previous reports in patients with melanoma 28 . Although more clinical work is needed to prospectively test and validate these observations, these data suggest that sequential therapy is not an optimal therapeutic approach.
Derivation of an intermittent combination therapy to suppress the expansion of BRAF-amplified clones
Although ineffective as monotherapy, ERK signaling inhibitors given in combination may raise the fitness threshold to prevent the expansion of heterogeneous BRAF amp subclones (Fig. 4d) . Combined RAFi, MEKi and ERKi treatment durably inhibited signaling and proliferation in A375 cells that were induced to express intermediate or high levels of BRAF V600E (Fig. 5a,b and Supplementary Fig. 5a) . A durable target inhibition was also observed in 1D-and 1D-EiR cells (Supplementary Fig. 5b ) and in other PDX models in vivo ( Supplementary Fig. 5c ). As expected, the three-drug combination produced the strongest antitumor effect against PDX1D and PDX1E, which was most apparent after drug withdrawal (Fig. 5c,d) . To determine whether the treatment was sufficient to suppress the growth of BRAF amp subclones, we intentionally stopped treatment early and allowed the tumors to regrow in the absence of the drugs. Tumors that regrew following discontinuation of two-drug regimens had higher BRAF CNs and levels of protein expression than the untreated tumors ( Fig. 5e) BRCA2  BTK  CDK12  CDKN2B  CRLF2  CSF3R  CTNNB1  DICER1  EGFR  EPCAM  EPHA3  EPHB1  ERBB4  ERCC4  FAT1  FGFR2  FLT1  FLT4  GATA2  GATA3  GSK3B  IDH1  IGF1  INHBA  INK4A  IRS1  IRS2  KDM5A  KDM5C  KDR  KMT2A  KMT2C  MDC1  MED12  MITF  NCOA3  NCOR1  NF1  NOTCH2  NOTCH3  NPM1  NTRK3  PAK7  PDGFRB  PIK3CA  POLE  PTCH1  PTEN  PTPRT  PAD50  RB1  RECQL4  RNF43  ROS1  RUNX1  SMO  STAG2  TERT  TGFBR1  TP53  TSC2  VEGFA  ZFHX3 Cancer type RAFi ERKi a r t i c l e s protein expression. Thus, the three-drug regimen imposed the highest fitness threshold to prevent the propagation of BRAF amp -tumor subpopulations ( Fig. 4d) . By coincidence, the triple-drug combination had a lower toxicity profile than the MEKi-ERKi combination (Supplementary Fig. 5d,e) . Addition of the RAFi diminished the inhibitory effect of the other drugs in normal tissue ( Supplementary  Fig. 5f ), suggesting that the ability of the RAFi to paradoxically activate ERK in BRAF WT cells ameliorates the toxicity of therapy.
To further reduce the toxicity associated with maximal inhibition of ERK activity (Supplementary Fig. 5d,e) , we evaluated the potential benefit of schemes involving intermittent drug administration (Fig. 6a) . Several administration schedules (schedules 2-6) were compared to the effect of continuous administration of the three drugs (schedule 1). The three drugs were administered together for 2 weeks every month (schedule 2) or for 4 d every week (schedule 5). The inhibitors were also administered in an alternating fashion (schedules 3 and 4) or dosed in a sequential intermittent fashion (schedule 6). Concurrent administration of the three drugs for 2 of 4 weeks (schedule 2) or for 4 of 7 d (schedule 5) had a similar antitumor effect as that with the continuous schedule ( Fig. 6b) . Regimens in which the drugs were not given concurrently were less effective. To determine whether treatment on schedule 5 completely suppressed tumor growth, we discontinued treatment after six cycles and monitored tumor growth for 180 d. No re-growth was observed during this time. Schedule 5 was further optimized by increasing the off-drug interval to produce a regimen that consisted of 3 d on treatment followed by 4 d off treatment (3/7), which maximally inhibited tumor growth without measurable toxicity in mice ( Fig. 6c and Supplementary Fig. 6a ).
Broader testing of the intermittent combination therapy
By imposing a high fitness threshold, the intermittent regimen may have a strong antitumor effect in a broader panel of PDX models. To evaluate this, we tested 13 PDX models of lung cancer and melanoma, which had varying levels of BRAF expression ( Fig. 6d) and multiple concurrent genetic co-alterations (Fig. 6e) . The intermittent treatment produced statistically significant tumor growth inhibition in 11/11 PDX models of BRAF V600 -mutant tumors (Fig. 6f,g and Supplementary Fig. 6a-i) . Specifically, of the 55 tumors tested, 42 (76%) regressed and 55 (100%) were inhibited after treatment. This approach inhibited growth in models with acquired (PDX1D-EiR and PDX7-EiR) or de novo (PDX21, PDX25 and PDX28) resistance to ERKi treatment ( Fig. 6f and Supplementary Fig. 6b,g,i) . It also inhibited tumors harboring various other alterations that have been reported to confer resistance to RAFi or MEKi therapy [29] [30] [31] [32] [33] [34] , including NF1, PTEN, IRS, EGFR and TSC2 (Fig. 6e, arrows) . Finally, the treatment had minimal antitumor effects in PDX models expressing BRAF WT ( Fig. 6g and Supplementary Fig. 6c,d) and did not produce toxicity in mice (Supplementary Fig. 6c-i) . These data suggest that the parameters that control the evolution of BRAF amp also regulate the selection of other resistance-causing alterations.
DISCUSSION
Parallel evolution has been described in hematologic malignancies 35, 36 , and when comparing primary and metastatic lesions in solid tumors 37 . Here, by using single-cell DNA sequencing, we found that parallel evolutionary tracts enabled the selection and propagation of distinct BRAF-amplified subclones. These occurred in the same tumor shortly after drug treatment, allowing the tumor to adapt while maintaining its intratumoral heterogeneity.
To explain the process driving the evolutionary selection of this alteration, we derived the fitness threshold model, where fitness threshold refers to the barrier that subclonal populations need to overcome to regain fitness in the presence of drug treatment. Drugs targeting different nodes of the same pathway have distinct mechanisms of actions and, as a consequence, they exert a different evolutionary selective pressure. As such, the level of BRAF amp that was required to overcome the effect of the drug differed between RAF, MEK and ERK inhibitors, with tumors treated with the latter able to tolerate higher levels of BRAF amp . This is probably why treatment with the ERKi produced a short-lived response in PDX models harboring low-level BRAF amp .
The fitness threshold model links the effect of the drug on its target with the evolutionary selection of resistance-causing alterations and has two immediate implications for the treatment of patients with cancer. The model predicts that sequential treatment is ineffective, a prediction that is supported by our findings that treatment with a RAFi followed by treatment with an ERKi led to a progressive increase in BRAF CN and that patients who were pre-treated with ERK signaling inhibitors did not respond well to subsequent treatment with another inhibitor of the pathway. As noted above, a concentrated effort is required to prospectively evaluate these observations in the clinic, as they may reshape how patients are enrolled into clinical trials.
The model also predicts that at a sufficiently high fitness threshold, a broader range of BRAF amp subclones, including those with high-level amplification, are at a fitness disadvantage and prevented from propagation. One way to achieve this is with concurrent targeting of the RAF, MEK and ERK kinases. It remains to be seen whether newer ERK signaling inhibitors with distinct mechanisms of actions (particularly inhibitors that target RAF dimers or phosphorylated ERK) are able to sufficiently raise the fitness threshold during monotherapy. We went a step further and identified an intermittent administration scheme that retained the negative effect of the three-drug combination on fitness while minimizing its toxicity in preclinical models. The intermittent administration regimen has the dual benefit of providing a recovery window, which allows for the drugs to be partially cleared, as well as of removing the strong positive selective pressure applied on the tumor by therapy. The intermittent three-drug combination caused regressions (~75%) and suppressed tumor growth (100%) in PDX models that harbored diverse co-alterations in addition to BRAF V600E . These findings are important not only because they serve as a proof of principle that intermittent administration enables concurrent delivery of multiple targeted therapies but also because they suggest that the fitness threshold model explains how other resistance-causing alterations are propagated during targeted therapy.
Over the ~5 years that ERK inhibitors have been available for clinical testing alongside RAF and MEK inhibitors, no clinical trials have evaluated the effect of the three-drug combination in patients. The intermittent regimen identified in our study warrants clinical testing, as it may halt the evolution of resistance and improve clinical outcomes in patients whose tumors harbor mutations of BRAF V600 .
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. a r t i c l e s of the eluate was combined with 10 µl of 2× Quick Ligation Reaction Buffer, 4 µl of 10 µM barcoded adaptor and 2 µl of Quick T4 DNA Ligase (New England BioLabs) and incubated at 20 °C for 15 min. The ligated product was then combined with 26.25 µl Agencourt AMPure XP magnetic beads (Beckman Coulter) (ligated product/magnetic bead ratio 0.35), thoroughly mixed and incubated at room temperature for 10 min. The complexes of the magnetic beads and DNA were washed twice with freshly prepared 80% ethanol, dried for 10 min at room temperature, eluted in 30 µl of EB buffer and quantified using a Qubit Fluorometer. The barcoded libraries were then pooled by mixing equal amounts (~20 ng each) and quantitated and PCR-enriched in duplicate using the NEBNext High-Fidelity 2× PCR Master Mix (New England BioLabs) containing up to 80 ng of pooled library and 2.5 µl of enrichment primers. The reactions were incubated for 30 s at 98 °C and then five cycles of 10 s at 98 °C, 30 s at 60 °C or 65 °C (depending on primer set) and 30 s at 72 °C, with a final 5-min incubation at 72 °C to ensure polished ends. Individual replicates were then combined, cleaned using the QIAamp DNA Mini Kit (Qiagen) and eluted in 50 µl EB buffer. Enriched libraries were assessed on a Bioanalyzer instrument (Agilent Technologies), quantified and sequenced on a HiSeq4000 instrument using PE 2 × 150 bp (Illumina).
Copy number analysis of single cells. Multiplexed single-cell sequencing libraries were split according to their unique barcode identifiers, which were specified by the first seven bases of the sequencing reads. Single-cell sequencing data were aligned to the human reference genome hg19 (or to the mouse genome mm10 in the case of stromal cells) using Bowtie 42 . Single cells with poor-quality reads were dropped from subsequent analyses. Sequencing reads were sorted, followed by removal of PCR duplicates, and then indexed using SAMtools 43 . CN assessment of single cells was performed using the Ginkgo5 pipeline 20 (http://qb.cshl. edu/ginkgo) with the following settings: variable bin size of 250 kb, bins based on simulations of 101 bp, and CBS segmentation. Bad bins and Y-chromosome pseudo-autosomal regions were masked, and the clustering was done using Manhattan distance and Ward linkage algorithms on integer CN values.
Subclonal diversity index. Clusters of genotypes were identified by hierarchical clustering, as noted above. The proportion of cells that belonged in each group (p) was used to calculate the Shannon diversity index with the formula: Dc = −Σ i (p i × ln(p i )), embedded in the R package 'vegan' , as described 44 . A Shannon index greater than 1 represents a high clonal diversity.
Dimensionality reduction. This was achieved by using eigenvector-based principal component analysis (PCA) on single-cell copy numbers with the 'xlstat' package. t-distributed stochastic neighbor embedding (t-SNE) was also used. For this, integer CN states of single cells were assembled in a Manhattan distance matrix followed by analysis with the tSNE package in R (perplexity 4, iterations 1,000, epoch 100). A third approach involved identifying chromosomal regions with heterogeneous copy number alterations in parental and resistant tumors, defined as those with an abundance of 20-80% (Supplementary Fig. 1f ). These were then used to distinguish BRAF amp subclonal populations.
Fluorescence in situ hybridization (FISH). FISH analysis was performed on formalin-fixed paraffin-embedded (FFPE) sections or cell line suspension, as described 45 . Cell lines were harvested and fixed in methanol:acetic acid (3:1) as per standard procedures. Three separate probe sets were designed to confirm the CN changes detected by single-cell sequencing: a two-color probe to detect BRAF and centromere 7 (control); a three-color probe to detect BRAF, RB1 and ALK; and a three-color probe to detect BRAF, RB1 and ATM. The bacterial artificial chromosome (BAC) or plasmid clones used in the probe mix were as follows: BRAF (RP11-788O6, RP11-1065D4 and RP11-133N19; labeled with red dUTP), centromere 7 (p7t1; labeled with green dUTP), RB1 (RP11-795F23 and RP11-305D15; labeled with Oorange dUTP), ALK (RP11-701P18, RP11-644H8 and RP11-229K3; labeled with green dUTP) and ATM (RP11-56J3 and RP11-241D13; labeled with green dUTP); all RP11 clones were from the Roswell Park Cancer Institute Genomics Shared Resource, and p7t1 was from the MSKCC Molecular Cytogenetics Core Facility. Probe labeling, tissue processing, hybridization, post-hybridization washing and fluorescence detection were performed according to standard laboratory procedures. Slides were scanned using a Zeiss Axioplan 2i epifluorescence microscope equipped with a megapixel charge-coupled device camera (CV-M4 + CL, JAI) controlled by Isis 5.5.9 imaging software (MetaSystems Group Inc, Waltham, MA). Metafer and VSlide module within MetaSystems were used to generate the virtual image of H&E and DAPI-stained sections.
Each probe was hybridized on a separate slide or section. For the cell lines, the entire hybridized area was scanned through a 63× or 100× objective lens, representative cells or regions were imaged, and a minimum of 50-200 discrete nuclei and 25 metaphases were scored. For paraffin tissue, the entire section was scanned under 63× or 100× objective lens, intratumoral heterogeneity was assessed, and representative regions were imaged through the depth of the tissue (compressed or merged stack of 12 z-section images were taken at 0.5 micron intervals). At least ten images per representative region were captured, and a minimum of 50-200 discrete nuclei were scored for each distinct region or sample. Amplification was defined as the ratio of gene of interest and control ≥2.0, >10 copies of the gene of interest (independent of control locus) or at least one small cluster of the gene of interest (≥4 signals resulting from a tandem repeat or duplication). In cells with high-level amplification, signals ≥20 could not be accurately counted and were therefore given a score of 20. Cells with 3~5 and 6~10 discrete copies of the gene of interest relative to the control were considered to be polysomic and high-polysomic, respectively.
Mass spectrometry detection of BRAF protein expression in vivo.
BRAF (total or BRAF V600E ) protein was quantified by selected reaction monitoringmass spectrometry (SRM-MS) as previously described 46 . Briefly, tissue sections (10 µM) from FFPE blocks were placed onto DIRECTOR microdissection slides (Expression Pathology Inc.) followed by deparaffinization and hematoxylin staining. Tumor areas were marked by a board-certified pathologist, and a 12-mm 2 section containing nearly 50,000 malignant cells was microdissected and solubilized to tryptic peptides using Liquid Tissue technology (Expression Pathology Inc.). The solution was subjected to SRM-MS analysis using stable isotope-labeled internal standard peptides for the quantification of BRAF V600E and total BRAF. Actin and tubulin quantification was monitored to verify sample quality and efficiency of microdissection. On-column injection resulted in 5 fmol of isotopically labeled internal standard peptides and 1 µg (~4,000 cells) of total tumor protein as measured by microBCA (Thermo Fisher Scientific). Instrumental analyses were performed on a TSQ Quantiva triple quadrupole mass spectrometer (Thermo Fisher Scientific) as previously described 47 .
Viability and clonogenic assays. For viability assays, 2 × 10 3 cells were seeded per well in 96-well plates and grown in the presence or absence of each inhibitor for 72 h. Viable cells were determined using the CellTiter-Glo (Promega) assay as described previously 48 . For siRNA studies, cells were grown in the presence of the siRNA for 72 h before drug treatment. siRNAs for the following targets were: BRAF (Dhamarcon SMARTpool: ON-TARGETplus BRAF siRNA L-003460-00) and nontargeting (Santa Cruz Control siRNA-A sc-37007). For clonogenic assays, cells were seeded at a density of 2 × 10 3 to 3 × 10 3 cells per well in triplicate into 6-well plates. They were cultured in the absence or presence of doxycycline and/or drug as indicated in complete medium for 10 d, with a medium change every other day. The plates were fixed with cold methanol and stained with 0.05% crystal violet.
Mouse studies. 6-to 8-week-old female immunodeficient nu/nu athymic (Envigo) and NSG (Jackson Laboratory) mice were maintained in compliance with IACUC guidelines. The mice that were implanted with xenografts were chosen for efficacy studies in an unbiased manner. In rare instances, mice were excluded if the subcutaneous tumors failed to engraft. Tumor-bearing animals were treated in a random fashion with drug or the appropriate vehicle control. Subcutaneous xenografts and tumor measurements were performed as described 15 in a nonblinded manner by a research technician who was not involved in the rest of the study. Treatment-related toxicity was determined by measuring animal weight and survival. Weight was reported either as an absolute value or as a percent change relative to the weight of the animal before treatment. Mouse survival was reported in Kaplan-Meier plots. In the figures in which the mouse weight was reported alone, no animal mortality was observed during treatment. All mouse studies were performed in compliance with institutional guidelines under an IACUC-approved protocol (Memorial Sloan Kettering Cancer Center no. 09-05-009).
Statistics and data analysis. Unless otherwise specified, Prism (GraphPad Software Inc.) was used for data analysis. The average tumor volume of each study arm was plotted over time. For five mice per cohort, the power to detect an odds parameter of 14.0 for each pairwise comparison, with a two-sided α level of 0.05, was 80%. Doubling times were calculated by fitting tumor volumes into exponential growth curves and determining their rate constants in Prism. Negative doubling times indicated tumor regression relative to the tumor size before treatment. Statistically significant differences in rate constants were determined by using the extra-sum-of-squares F test (with P < 0.05) embedded in Prism. Unless otherwise stated, groups were compared using an unpaired t-test with correction for multiple comparisons as needed. This included the comparisons of BRAF segment counts, CN, protein expression and tumor volumes.
Data availability. The sequencing data generated in this project are available as supplementary files.
